No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
SEC filings
10-K, 10-Q, 8-K, 20-F and 40-F reports Adaptimmune Therapeutics PLC filed with the SEC, newest first.
Livermore lists each filing's form, 8-K items and dates only. To read a filing, open it on SEC.gov; an 8-K's press release or other attachments, such as exhibit 99.1 for Item 2.02, are in the filing index.
SEC filings by Adaptimmune Therapeutics PLC
Filed
Form
8-K items
Period
Document
Filing index
Oct 20, 2025
8-KCurrent report
3.01Item 3.01: Notice of delisting or failure to meet a listing rule; transfer of listing7.01Item 7.01: Regulation FD disclosure9.01Item 9.01: Financial statements and exhibits
1.02Item 1.02: Termination of a material definitive agreement2.01Item 2.01: Completion of an acquisition or disposition of assets9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement2.05Item 2.05: Costs of exit or disposal activities (restructuring)5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements7.01Item 7.01: Regulation FD disclosure9.01Item 9.01: Financial statements and exhibits
5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
2.02Item 2.02: Results of operations and financial condition (earnings release)2.05Item 2.05: Costs of exit or disposal activities (restructuring)9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement2.03Item 2.03: New direct financial obligation, such as new debt or an off-balance-sheet obligation7.01Item 7.01: Regulation FD disclosure9.01Item 9.01: Financial statements and exhibits
